Effects of fluvastatin on endothelium-derived hyperpolarizing factor- and nitric oxide-mediated relaxations in arteries of hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 5-6, 2004, Pages 354-359

  Kansui, Yasuo ^a   Fujii, Koji ^a   Goto, Kenichi ^a   Abe, Isao ^a   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Endothelial dysfunction; Endothelium derived hyperpolarizing factor; Mesenteric arteries; Nitric oxide; Rat; Statins

Indexed keywords

ACETYLCHOLINE; ARGININE; CHOLESTEROL; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FLUINDOSTATIN; INDOMETACIN; NITRIC OXIDE; NORADRENALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HYPERTENSION; MALE; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ACETYLCHOLINE; ANIMALS; BIOLOGICAL FACTORS; FATTY ACIDS, MONOUNSATURATED; HYPERTENSION; INDOLES; MALE; NITRIC OXIDE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VASODILATION;

EID: 3042524990     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.04011.x     Document Type: Article

References (29)

1. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 1989; 65: 1-21.
2. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br. J. Pharmacol. 1988; 95: 1165-74.
3. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 1996; 78: 415-23.
4. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396: 269-72.
5. Yamamoto Y, Imaeda K, Suzuki H. Endothelium-dependent hyperpolarization and intracellular electrical coupling in guinea-pig mesenteric arterioles. J. Physiol. 1999; 514: 505-13.
6. Fujii K, Ohmori S, Tominaga M et al. Age-related changes in endothelium-dependent hyperpolarization in the rat mesenteric artery. Am. J. Physiol. 1993; 265: H509-16.
7. Fujii K, Tominaga M, Ohmori S et al. Decreased endothelium-dependent hyperpolarization to acetylcholine in smooth muscle of the mesenteric artery of spontaneously hypertensive rats. Circ. Res. 1992; 70: 660-9.
8. Onaka U, Fujii K, Abe I, Fujishima M. Antihypertensive treatment improves endothelium-dependent hyperpolarization in the mesenteric artery of spontaneously hypertensive rats. Circulation 1998; 98: 175-82.
9. Goto K, Fujii K, Onaka U, Abe I, Fujishima M. Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction. Hypertension 2000; 36: 581-7.
10. Goto K, Fujii K, Onaka U, Abe I, Fujishima M. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 2000; 36: 575-80.
11. Klag MJ, Ford DE, Mead LA et al. Serum cholesterol in young men and subsequent cardiovascular disease. N. Engl. J. Med. 1993; 328: 313-18.
12. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
14. Levine GN, Keaney Jr JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. 1995; 332: 512-21.
15. Treasure CB, Klein JL, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 1995; 332: 481-7.
16. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
17. Sacks FM, Pfeffer MA, Moye LA et al. for the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. N. Engl. J. Med. 1996; 335: 1001-9.
18. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-82.
19. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-30.
20. Wassmann S, Laufs U, Baumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-7.
21. Kansui Y, Fuju K, Goto K, Abe I, Iida M. Angiotensin II receptor antagonist improves age-related endothelial dysfunction. J. Hypertens. 2002; 20: 439-46.
22. Glorioso N, Troffa C, Filigheddu F et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-6.
23. Wagner AH, Köhler T, Rückshloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 61-9.
24. 2+ homeostasis. Eur. J. Pharmacol. 2001; 415: 217-24.
25. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 1998; 273: 24266-71.
26. Vanhoutte PM. Endothelium-derived free radicals: For worse and for better. J. Clin. Invest. 2001; 106: 1521-30.
27. Matoba T, Shimokawa H, Nakashima M et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J. Clin. Invest. 2000; 106: 1521-30.
28. Goto K, Fuju K, Kansui Y, Abe I, Iida M. Critical role of gap junctions in endothelium-dependent hyperpolarization in rat mesenteric arteries. Clin. Exp. Pharmacol. Physiol. 2002; 29: 595-602.
29. Tsunekawa T, Hayashi T, Kano H et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104: 376-9.